Reported value$17.1M510,873 shares at $33.43
For this personNormal for them32 buys · 0 sales on file
Similar buys beat S&P43%670 cases · all buys 46%
Worth a closer look
- Open-market purchase with their own money (Form 4 code P), not a grant or option exercise.
Reasons for caution
- Other insiders sold $492M in the same 90 days, more than was bought (0% of it pre-planned).
- Bought by a 10% owner or investment firm, whose reasons often differ from an executive's.
- Small next to what they already own (holding up 0.4%).
- Similar past buys beat the S&P 500 only 43% of the time (670 cases); the typical one trailed it by 2.9%.
What happened after this filing
7 days
+0.7%
+0.9% vs S&P
30 days
Pending
due Nov 18
90 days
Pending
due Jan 17
Insider Twins: past buys with the same traits
1 insider buying · no CEO or CFO · $1M+ · stock up over 3 months
GME Dec 21, 2020 +1183.4% vs S&PAEVA Mar 31, 2025 +410.2% vs S&PHYMC Oct 16, 2025 +282.5% vs S&PFULC Jan 24, 2023 -82.8% vs S&PFULC Jan 6, 2023 -80.3% vs S&PFWRD Feb 17, 2026 -77.3% vs S&PWhat we couldn't check
- Why they traded. Filings don't say, and we don't guess.
- Company news after the filing, and any private terms.
Summary
Nippon Life Insurance Co (a 10% owner) bought $17M of CRBG at about $33.43 on Oct 15, 2026, reported to the SEC on Oct 19, 2026. Buys like this beat the S&P 500 43% of the time since 2020, against 46% for all insider buys. We found 1 point that make it worth a closer look and 4 reasons for caution. History, not a prediction.
Following. We'll keep this page updated; see everything you follow. Want an email when the 30 and 90-day results land? Use the CRBG alerts below.
Written by fixed rules from SEC filings and our measured history, not by an AI model. Public data only. History, not a prediction, and not investment advice.